Gene therapy for cystic fibrosis lung disease

Stephanie G. Sumner-Jones, Deborah R. Gill and Stephen C. Hyde

Gene Medicine Group, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
United Kingdom Cystic Fibrosis Gene Therapy Consortium

Abstract

Cystic fibrosis (CF) is characterised by respiratory and pancreatic deficiencies that stem from the loss of fully functional CFTR (CF transmembrane conductance regulator) at the membrane of epithelial cells. Current treatment modalities aim to delay the deterioration in lung function, which is mostly responsible for the relatively short life expectancy of CF sufferers; however none have so far successfully dealt with the underlying molecular defect. Novel pharmacological approaches to ameliorate the lack of active CFTR in respiratory epithelial cells are beginning to address more of the pathophysiological defects caused by CFTR mutations. However, CFTR gene replacement by gene therapy remains the most likely option for addressing the basic defects, including ion transport and inflammatory functions of CFTR. In this chapter, we will review the latest preclinical and clinical advances in pharmacotherapy and gene therapy for CF lung disease.

Introduction

Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder among Caucasians. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene identified by positional cloning in 1989 [1–3], which encodes a chloride (Cl⁻) channel expressed in the epithelia of many tissues. The gene encodes a single polypeptide chain of 1480 amino acids, with a predicted molecular weight of around 168 kDa [1]. The CFTR protein is embedded in the apical membrane of epithelial cells and is made up of distinct structural domains, including two membrane spanning domains (MSDs), two nucleotide binding domains (NBD) containing conserved motifs for ATP binding and hydrolysis, and a regulatory domain (R) [4]. The CFTR protein, a member of the ABC family of proteins, normally functions as a cAMP-activated Cl⁻ channel [5], and has been shown to interact with other ion channels and transporters, such as the amiloride-sensitive epithelial sodium channel, ENaC (recently reviewed by Berdiev et al. [6]) and the outwardly rectifying chloride channel (ORCC) (reviewed by Kunzelmann, [7]).
CFTR mutations

The Cystic Fibrosis Mutation Database (http://www.genet.sickkids.on.ca) currently lists 1604 mutations located throughout the gene and affecting all domains of the protein. The most common mutation ΔF508, is found in 70% of disease alleles [2], and is caused by a deletion of three consecutive base pairs, resulting in the loss of a phenylalanine (F508) [1]. Mutations in the CFTR gene are grouped into five classes, based on their effect on CFTR protein expression and/or function: Class I–III mutations commonly cause severe disease phenotypes, Class IV and V mutations tend to be associated with milder disease, although not systematically for lung disease which can be highly variable even within identical genetic backgrounds [8, 9].

Pathophysiology of CF lung disease

Mutations in CFTR disrupt transport in the epithelium of several tissues, which results in the production of abnormally thick, sticky mucus. The main cause of morbidity in CF is lung disease [10], with deterioration of lung function and pulmonary failure being the cause of death for the majority (>90%) of patients. The production of thick, sticky mucus in the lumen of the lung impedes mucociliary clearance [11], a consequence of which is chronic inflammation and recurrent bacterial infections (typically Pseudomonas aeruginosa and Burkholderia cepacia complex), in a self-perpetuating cycle that leads to the progressive destruction of lung tissue [10]. In severe cases, P. aeruginosa can form antibiotic resistant biofilms in the lumen of the airways, the presence of which correlates with a decline in lung function [12].

Airway epithelial cells (AEC) are covered in air surface liquid (ASL), made up of a mucus layer that traps potentially harmful particulate matter that is inhaled, and the periciliary liquid (PCL) layer. The PCL provides a less viscous layer for the cilia to beat and remove the mucus (containing the trapped particles) from the airways by mucociliary clearance. The PCL also acts as a lubricant between the mucus layer and the mucins tethered to the cell surface to facilitate cough clearance [13, 14]. Finally PCL contains antimicrobial peptides and proteins (e.g., defensins, lysozyme, lactoferrin and anti-microbial surfactant proteins) to fight pathogens [15]. In CF these processes are disrupted, causing dysregulation of liquid movement, and lung infection and inflammation [16].

The low volume hypothesis to explain CF lung disease

The low volume hypothesis [17], also know as the ‘isotonic volume transport/mucus clearance’ theory, implicates reduced ASL volume as the initiating event in CF lung pathology. The airway epithelium is thought to regulate ASL
volume so that the height of the PCL layer is approximately the same as that of the extended cilia on the cell surface of the epithelium (around 7 μm) [18], allowing them to beat efficiently. In CF airways, the ASL volume and hence PCL height is decreased, making the mucus layer sticky and harder to move [18]. The resulting flattening of the cilia prevents them from beating [19], causing mucus to adhere to cells [14]. Together these events lead to defective mucociliary clearance, initiating the chronic cycle of infection and inflammation characteristic of CF lungs (reviewed by Boucher, 2007 [20]).

There is now a significant amount of evidence to support the low volume hypothesis in primary human cell culture and mouse models. Most recently, accelerated Na⁺ absorption, leading to a decrease in PCL height and reduced mucociliary clearance was demonstrated in vivo in the ENaCβ over-expressing mouse (reviewed by Mall, 2008 [21]) and in primary air-liquid interface (ALI) cultures from CF patients [18, 19].

The recent availability of the ENaCβ over-expressing mouse, with its lung pathology that closely mirrors that of CF patients, has provided a powerful tool for understanding the links between CFTR deficiencies and the complex pathophysiology of CF. For example sterile inflammation is also observed in these mice [22], supporting the hypothesis that inflammation can occur independently of infection.

**Pharmacological approaches to treat CF lung disease**

Pharmacological processes that restore effective ASL height and mucociliary clearance in CF patients could be targeted to upregulate CFTR activity, modify alternative channels (ENaC, Calcium-activated Cl⁻ channel (CaCC)), or rehydrate the ASL with hyperosmotic agents such as inhaled mannitol and hypertonic saline [23, 24]. Current approaches to pharmacological correction of CFTR include: 1) drugs that increase the level of CFTR protein synthesised, 2) CFTR correctors to increase trafficking out of the ER, and 3) CFTR potentiators that correct gating defects of CFTR at the membrane (Fig. 1).

**Drugs that increase CFTR protein levels**

Several strategies to increase the amount of CFTR at the cell surface have been investigated, including increasing overall transcription levels with butyrate [25] or sodium 4-phenylbutyrate (4-PBA) [26], although neither has had an impact in clinical trials. Several drugs that promote read-through of nonsense stop codons have been shown to produce full-length CFTR, including aminoglycoside antibiotics (e.g., gentamicin) [27, 28] or the recently developed PTC124 [29]. The latter appears capable of improving electrophysiological features of nasal epithelium and several clinically relevant outcome measures (FEV1, FVC, circulating neutrophils) [30–32]. Interestingly it has been
reported that a drug such as PTC124 may not be effective in all cases of premature stop codons, due to exonic skipping which removes the early stop codon from the mature mRNA [33].

**CFTR correctors, drugs to increase trafficking of CFTR**

Enhancing trafficking of CFTR using chemical chaperones can increase CFTR levels in the membrane in preclinical studies [34–36]. Recent efforts to identify more CFTR-specific correctors have involved high-throughput screening [37–40]. The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, shows promis-
ing correction of the CF defect in vitro [41] and is currently in Phase I/II clinical studies expected to conclude in 2010. KM1160, a much more potent analogue of sildenafil, is in early stages of development [42]. A different corrector, Miglustat, functions through inhibition of α-1,2-glucosidase, thus preventing rapid degradation of ΔF508 in the ER, and has shown promise in multiple preclinical studies [43–47]. Miglustat is now in a Phase II trial (Actelion). VX-809 is a ΔF508 CFTR corrector that was discovered through a collaborative programme, between Vertex and Cystic Fibrosis Foundation Therapeutics Inc. It recently entered a Phase II safety/efficacy study [48]. Results of both these studies are eagerly awaited.

**CFTR potentiators, drugs that increase conductance at the apical membrane**

Other potential drug therapies have been based on increasing the activation of CFTR, by increasing the level of cyclic nucleotides in the cell using phosphodiesterase (PDE) inhibitors such as milrinone [49, 50], or by direct activation with curcumin [51], genistein or 8-cyclopentyl-1,3-dipropylxanthine (CPX) [52]. The most promising advances involve Vertex compound VX-770 [53], a drug that increases the open probability and Cl– conductance of CFTR; it has completed a Phase IIa trial [54] and entered the FDA registration programme in 2009.

**Modulation of other ion channels**

Upregulation of CaCC (Ca2+-activated Cl– channel) by Denufosol and Moli1901 (Lancovutide®) was recently demonstrated to be a safe and tolerable way of inducing some Cl– transport via non-CFTR channels [55–58]. Further evaluation of efficacy in CF patients for both drugs is ongoing.

Alternatively, ENaC activity could be inhibited in order to decrease the elevated Na+ absorption seen in CF airways. The Parion compound 552-02 [59] is a recent improvement on the ENaC inhibitor, amiloride, and has already entered clinical trials, including one for CF, which is currently under way.

Inhibition of serine proteases can prevent activation of ENaC, but most candidates have not yet proceeded beyond preclinical studies [60]. A recent small-molecule inhibitor of proteases involved in ENaC regulation, Camostat, was tested with some success in sheep aerosol studies, improving mucociliary clearance for several hours after administration [61]. Partial correction (75% towards normal) of the Na+ transport defect in the nose of CF patients was reported [62], confirming that this is a promising candidate for evaluation in the clinic for CF lung disease.

Although these data are encouraging, the majority of these new drug treatments have only modest ability to correct the CF defect, do not act on all
CFTR mutations, and even if successful, may only benefit a small proportion of patients depending on their genotype. It is also likely that the pharmacological approaches discussed here could require use in combination with each other for optimal correction of the CF ion transport defects, for example a corrector with a potentiator, and simultaneously adjusting ENaC activity with a third component; this may limit their use in the clinic and will certainly take time to evaluate in trials.

**Gene therapy clinical trials**

The basic concept of gene therapy involves introducing a gene into target cells to prevent or slow the progression of a disease. CF is a good candidate for this technology as it is primarily caused by mutations in a single gene, a normal copy of which could be delivered to patients via topical delivery to the lung, without invasive techniques or surgery. Moreover, a gene complementation approach would directly target the cause of the disease and could correct many aspects of the complex lung pathology. A single therapy to treat the underlying defect could greatly reduce the high therapeutic burden that CF patients currently have to endure. In addition, one therapy might be suitable to treat subjects with a wide variety of mutations, meaning that a single treatment strategy could be relevant to all patients. Proof of principle for both viral and non-viral CFTR gene transfer was quickly established in CF patients [63] and to date, 25 trials have been completed involving approximately 450 CF individuals (see Griesenbach, 2009 [64]).

**Adenovirus and Adeno-Associated Virus**

Two DNA viral vectors, adenovirus (Ad) and adeno-associated virus (AAV), have been evaluated in CF gene therapy clinical trials. Trials with Ad vectors have been disappointing, compared with preclinical studies, both in terms of persistence of gene expression and the level of gene transfer in the human airways. Gutless adenovirus (also referred to as helper-dependent Ad), in which all of the viral genome is removed (apart from the inverted terminal repeats (ITRs) and the viral packaging sequence) [65] have shown extended duration of transgene expression, with reduced toxicity and immunogenicity in mice compared with previous generations of Ad [66], but re-administration remains problematic due to the presence of viral capsid proteins [67].

An alternative viral vector that has been investigated in CF clinical studies is the non-pathogenic AAV. Phase I and II clinical trials administering a single dose of AAV2 expressing CFTR to the nose [68–71] and lungs [72, 73] of CF patients were deemed safe and resulted in consistent detection of vector-derived DNA for between 30 days and 10 weeks after delivery. CFTR mRNA was very rarely detected in the trials, although two studies reported transient
correction of the Cl− conductance defect in the nose for up to 2 weeks after delivery [69, 70]. Treatment did not result in any detectable clinical benefit in lung function [71] and neutralising antibodies against the vector were detected in the serum [72, 73]. Two trials to re-administer the virus have been performed, with a similar lack of clinical benefit [74, 75]. Once again, this has been disappointing in comparison with preclinical studies in mice in particular, but is partly attributable to a paucity of AAV2 receptors on the apical membrane of human cells [76].

Thus, alternative serotypes with potentially improved tropism for airway epithelial cells are being investigated. AAV5 and AAV6 appear to transduce airway epithelial cells more efficiently than AAV2 [77, 78], and up to 90% transduction efficiency was recently reported in mouse airways with AAV6 using the hybrid chicken β-actin/rabbit β-globin promoter/intron with the human CMV immediate early enhancer (CAG) [79].

The lack of efficiency in the repeat administration clinical studies [74, 75] is in keeping with some preclinical studies showing an inability to re-administer AAV2 and AAV5 in airways of animals, unless genotypes were switched for re-administration [80–83]. Interestingly, it has been demonstrated that AAV9 serotype virus could be re-administered successfully to murine airways 1 month after the initial dose [84].

In addition to difficulties with tropism and immune responses, the utility of AAV for CF has been hampered by the limited packaging capacity of most rAAV vectors (<5 kb). Advances in this field have included development of miniCFTR genes that may be packaged more efficiently [85–88], including safety studies in non-human primates [89] and functional studies in mice [90], and the discovery that AAV2/5 could in fact package large genomes (up to 8.9 kb) with a reasonably yield compared with other rAAV pseudotypes (1 to 4 and 7 to 9) [91]. Together with evidence suggesting that AAV vectors may be able to target progenitor cells of the mouse lung [92], thus avoiding the need for repeat administration, this work continues to make incremental improvements.

**Negative strand RNA viruses**

The murine parainfluenza virus type 1 [or Sendai virus (SeV)], the human respiratory syncytial virus (RSV) and the human parainfluenza virus type 3 (PIV3) are negative strand RNA viruses whose life cycle is completed in the cytoplasm. They have all been shown to transfect AECs efficiently via the apical membrane [93, 94], and express functional CFTR channels in vivo [95], but elicit an immune response that currently inhibits repeated administration [96]. Although such viruses may be useful for acute diseases that require only transient gene expression, in the context of CF their use is for now restricted to preclinical proof of principle studies, until the immunological barriers to repeat administration can be resolved.
Lentiviruses

Lentiviruses are retroviruses that transduce non-dividing cells including terminally differentiated AECs. The viral dsDNA genome stably integrates into the genome of transduced cells after its RNA has been reverse transcribed, so expression is likely to last for the lifetime of the cell (approximately 17 months for AECs, [97]). VSVG-pseudotyped HIV-derived lentivirus carrying the CFTR gene transiently and partially corrected the Cl⁻ defect in CF knockout mouse nose for up to 46 days, although pre-treatment with the tight junction opener lysophosphatidylcholine was necessary [98]. There have been attempts to improve the tropism of lentivirus by pseudotyping with envelope glycoproteins from the filoviruses Ebola or Marburg [99], GP64 of baculovirus [100], the spike envelope glycoprotein of the SARS virus [101] and the F and HN proteins of SeV [102]. This latter vector, F/HN-SIV, was able to transduce polarised epithelial cells from both the apical and basolateral side and importantly, murine AEC in vivo without the need for pre-conditioning, with gene expression in vivo persisting for at least 17 months, i.e., the lifetime of AECs [97, 103]. This is consistent with gene expression for up to 12 months in mouse nose with GP64-FIV [100]. As with other viruses, it will be important that researchers address the challenge of multiple repeat administrations without loss of efficacy, or find ways of targeting stem cell populations of the airways, to treat the chronic aspects of CF lung diseases.

Non-viral vectors for CF gene therapy

The need for effective long-term repeated administration to treat CF lung disease had led to the investigation of non-viral vectors, which take the form of circular plasmid DNA (pDNA) delivered to cells as naked pDNA in diluents such as PBS, saline or water, or complexed with agents such as lipids or poly-cations as protection from extracellular degradation and to aid cellular entry. The relative lack of efficiency compared with viral vectors is counterbalanced by reduced safety concerns regarding integration, more flexible and easier production methodology, extended storage and an unlimited packaging capacity [104, 105].

Non-viral Phase I clinical trials to deliver pDNA expressing CFTR began in the mid 1990s, with a variety of cationic liposome formulations delivered to the nose and/or lungs of CF patients. In general, gene transfer was well tolerated and evidence of CFTR gene transfer (as measured by vector-specific mRNA or CFTR-mediated chloride transport) has been established in some, but not all, studies (reviewed in Rosenecker et al., 2006 [106]).

One side effect of lipid formulations has been the transient mild flu-like symptoms reported by Ruiz and Alton in the lung trials of GL67:DOPE:DMPE-PEG/pDNA [107, 108]. This inflammation may be related to the stimulation of the Toll-like receptor 9 by bacterially-derived CpG dinucleotides in the formu-
lation [109, 110]. In a bid to reduce this response, the UK CFGT Consortium has generated a CpG-free pDNA [111], for CF clinical trials now under way. The deletion of CpG motifs is one of the latest aspects of plasmid development programmes in the field of CF gene therapy. A common feature of previous trials has been the transient nature of any correction that was measured. Persistence of expression has been improved in preclinical studies by swapping viral promoters such as CMV (cytomegalovirus) for human promoters including UbC (polyubiquitin C) and EF-1α (elongation factor 1-α) [112, 113]. Similarly specificity has been improved in mice using the human cytokeratin (K18) and FOXJ1 promoters which both directed epithelial cell-specific transgene expression in mice [114, 115]. Clinical trial data will confirm whether the modifications to the DNA construct have improved the duration and tolerability of gene transfer in the nose and lungs of CF patients. Table 1 summarises the features of recent non-viral vector developments in the context of airway gene therapy.

Cationic polymers as mediators for CF plasmid DNA gene therapy

A particular polycation that has shown promise for lung gene therapy is polyethylenimine (PEI), the most commonly used forms of which are 25 kDa branched PEI and 22 kDa linear PEI. Although not used in lung gene therapy clinical trials to date, PEI/pDNA complexes have led to successful gene delivery in a clinically relevant model of aerosol gene delivery [116], and work towards improving the formulation by concentrating the particles has shown promising results in murine airway studies [117]. Following comparison of over 25 different non-viral formulations, concentrated 25 kDa PEI has been selected as a ‘Wave 2’ product by the UK CFGT Consortium. Additional improvements may also come from the field of integrases, with the recent demonstration that mice treated with integrase-encoding and reporter constructs complexed with PEI expressed the reporter protein longer than those treated with a non-integrase-encoding construct [118].

The only cationic polymers used in clinical trials for CF gene therapy to date have been compacted DNA nanoparticles, which consist of a single molecule of pDNA compacted with a 30-mer lysine polymer covalently linked to polyethylene glycol (PEG) [119]. The advantage of this gene transfer agent is the identification of its receptor for cell uptake, nucleolin [120] and nuclear translocation bypassing the endosomal pathway. A Phase I study resulted in detection of vector-derived DNA 3 days after dosing in nasal epithelium of CF patients, and partial to complete correction of the Cl− transport defect in some patients [121].

Modifier genes and future directions

It is clear that the genotype of CF patients does not entirely predict the course of disease, particularly the rate of decline in lung function. A number of stud-
| Construct description | Model Feature | Ref. |
|-----------------------|---------------|------|
| pCUBI 1.1 kb I/E hCMV enh, human Lung instillation in mice | Duration for over 12 weeks vs pCF1 (4 weeks) | [112] |
| ubiquitin B prom/intr (hCMV I/E enh/prom and hybrid int) | | |
| pUbLux 1.2 kb of human polyubiquitin C prom, Lung instillation in mice | >26 weeks vs viral enh/prom constructs: pCIKLux (hCMV I/E enh/prom and hybrid int) and pSIKLux (SV40 enh/early prom.) (1-7 d, ±14 d, ±14 d) | [113] |
| pEFLux 1.3 kb of hEFI gene, including prom, Lung instillation in mice | >4 weeks vs viral enh/prom constructs as above, pPLdLux (SV40 enh/prom) (>7 days, ±14 d, ±21 d) and pPLdLux (hCMV I/E enh/prom and hybrid int), | [113] |
| pG4-hCEFI CpG-free I/E hCMV enh, hEF1 prom. to Lung instillation in mice | Stable expression to >56 days, and no inflammatory response, compared with CpG-rich pG1-CMV (=pCIKLux) (<14 d duration, high inflammatory response) | [111] |
| FoxJ1 1 kb of FoxJ1 genomic region and mouse transthyretin (TTR) gene in transgenic mice | Tissue and cell specificity:氣發細胞, mouse transthyretin (TTR) gene in transgenic mice | [115] |
| K18mLacZ 2.2 kb of K18 5' promoter proximal flank sequence, KRT18 promoters, and first intron/promoter with mutated cryptic splice site and enhancer sequences, KRT18 promoters, FoxJ1 promoter, and FoxP1 enhancer region and exon 2 fragment (from pEFLux) | Lung expression in mouse | [114] |

Abbreviations: enh, enhancer; prom, promoter; int, intron; I/E hCMV, immediate/early human cytomegalovirus; hEFI, human elongation factor 1α; K18/KRT18, cytok-
ies have attempted to identify modifier genes for different aspects of CF, as reviewed by Collaco and Cutting (2008) [122]. Lead candidates include inflammatory mediators and cytokines [122], and most recently IFRD1 [123], as well as gene polymorphisms that affect the response to bacterial infection (beta-defensins [124, 125], 8.1 ancestral MHC haplotype [126] and IL10 [127, 128]). In a disease such as CF where many factors influence the course of disease, with different clinical parameters to take into account (lung function, bacterial burden, inflammation), the identification of significant modifier genes will require large population studies. Ultimately this could provide new targets for anti-inflammatory drugs or gene silencing by RNAi strategies [129] to ameliorate disease.

Indeed it is likely that gene silencing therapies, including shRNA in pDNA constructs, will be evaluated that are not directly based on modifier genes, but on the general pathophysiology of CF. For example, a reduction in the transcription factor nuclear factor kappa B (NFκB), which regulates many pro-inflammatory cytokines and plays a central role in the exaggerated innate immune response in CF [130], or the ER-membrane protein BAP31, involved in blocking misfolded ΔF508 CFTR [131], may be beneficial. With further improvements in non-viral gene transfer, gene silencing may become a realistic treatment option.

**Conclusion**

No single, novel, therapeutic approach to CF treatment has yet shown sufficient promise to stand out in the field. However as our understanding of the molecular processes in the CF lung deepens with better preclinical models to evaluate them, it is becoming clearer that early and broad intervention will be necessary to prevent the multifaceted defects that accompany CFTR mutations. Pharmacological approaches are heading into clinical trials at a regular pace, with some preclinical studies showing correction of several major defects. Although the challenges of finding a safe and effective formulation permit only slow progress, gene therapy still provides a great opportunity for an ‘all-round’ therapeutic intervention.

**Acknowledgements**

We thank Dr Hazel Painter and Anna Lawton for helping with the design of the figure. Work in our laboratory is funded by a grant from the UK Cystic Fibrosis Trust to the UK CF Gene Therapy Consortium (www.cfgenetherapy.org.uk).

**References**

1 Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 245: 1066–1073
2 Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. *Science* 245: 1073–1080
3 Rommens JM, Zengerling-Lentes S, Kerem B, Melmer G, Buchwald M, Tsui LC (1989) Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis. *Am J Hum Genet* 45: 932–941
4 Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. *Nature* 346: 362–365
5 Sheppard DN, Welsh MJ (1999) Structure and function of the CFTR chloride channel. *Physiol Rev* 79: S23–45
6 Berdiev BK, Qadri YJ, Benos DJ (2009) Assessment of the CFTR and ENaC association. *Mol Biosyst* 5: 123–127
7 Kunzelmann K (2001) CFTR: interacting with everything? *News Physiol Sci* 16: 167–170
8 Rowntree RK, Harris A (2003) The phenotypic consequences of CFTR mutations. *Ann Hum Genet* 67: 471–485
9 Zielenski J (2000) Genotype and phenotype in cystic fibrosis. *Respiration* 67: 117–133
10 Robinson M, Bye PT (2002) Mucociliary clearance in cystic fibrosis. *Pediatr Pulmonol* 33: 293–306
11 Pier GB (2000) Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. *Proc Natl Acad Sci USA* 97: 8822–8828
12 Wanner A, Salathe M, O’Riordan TG (1996) Mucociliary clearance in the airways. *Am J Respir Crit Care Med* 154: 1868–1902
13 Knowles MR, Boucher RC (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest* 109: 571–577
14 Aarbiou J, Rabe KF, Hiemstra PS (2002) Role of defensins in inflammatory lung disease. *Ann Med* 34: 96–101
15 Chambers LA, Rollins BM, Tarran R (2007) Liquid movement across the surface epithelium of large airways. *Respir Physiol Neurobiol* 159: 256–270
16 Boucher RC (1994) Human airway ion transport. Part one. *Am J Respir Crit Care Med* 150: 271–281
17 Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. *Cell* 95: 1005–1015
18 Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC (2001) The CF salt controversy: in vivo observations and therapeutic approaches. *Mol Cell* 8: 149–158
19 Boucher RC (2007) Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. *Annu Rev Med* 58: 157–170
20 Clunes MT, Boucher RC (2008) Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. *Curr Opin Pharmacol* 8: 292–299
21 Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. *N Engl J Med* 349: 1433–1441
22 Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reine P, Lenoir G et al. (2007) In vitro prediction of stop-codon suppression by intravenous gen-
tamicin in patients with cystic fibrosis: a pilot study. *BMC Med* 5: 5

29 Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. *Nature* 447: 87–91

30 Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. *Lancet* 372: 719–727

31 Sermet-Gaudelus I, De Boeck K, Casimir G, Leal T, Vermeulen F, Mogenet A, Roussel D, Hage F, Hansens L, Constantine S et al. (2008) Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124. *Pediatric Pulmonology* Suppl. 31: 313

32 Kerem E, Yaakov Y, Armoni S, Pugatsch T, Shoseyov D, Cohen M, Blau H, Hirawat S, Reha A, Elfring G et al. (2008) PTC124 induces time-dependent improvements in Chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis. *Pediatric Pulmonology* Suppl. 31: 294

33 Aznarez I, Zielenski J, Rommens JM, Blencowe BJ, Tsui LC (2007) Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X. *J Med Genet* 44: 341–346

34 Egan ME, Glockner-Pagel J, Ambrose C, Cahill PA, Pappoe L, Balamuth N, Cho E, Canny S, Wagner CA, Geibl J et al. (2002) Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. *Nat Med* 8: 485–492

35 Rubenstein RC, Egan ME, Zeitlin PL (1997) *In vitro* pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. *J Clin Invest* 100: 2457–2465

36 Rubenstein RC, Zeitlin PL (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. *Am J Respir Crit Care Med* 157: 484–490

37 Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. *J Clin Invest* 115: 2564–2571

38 Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M et al. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. *Am J Physiol Lung Cell Mol Physiol* 290: L1117–1130

39 Wang Y, Bartlett MC, Loo TW, Clarke DM (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. *Mol Pharmacol* 70: 297–302

40 Wang Y, Loo TW, Bartlett MC, Clarke DM (2007) Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. *J Biol Chem* 282: 33247–33251

41 Dormer RL, Harris CM, Clark Z, Pereira MM, Doull IJ, Norez C, Becq F, McPherson MA (2005) Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. *Thorax* 60: 55–59

42 Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas DY, Hanrahan JW (2008) Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. *Mol Pharmacol* 73: 478–489

43 Norez C, Wilke M, Bijvelds M, Jorna H, Melin P, De Jonge HR, Becq F (2006) Rescue of functional deltaF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. *FEBS Lett* 580: 2081–2086

44 Antigny F, Norez C, Becq F, Vandebrouck C (2008) Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. *Cell Calcium* 43: 175–183

45 Noel S, Wilke M, Bot AG, De Jonge HR, Becq F (2008) Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojirimycin) in cystic fibrosis epithelial cells. *J Pharmacol Exp Ther* 325: 1016–1023

46 Dechecchi MC, Nicolis E, Norez C, Bezzareri V, Borgatti M, Mancini I, Rizzotti P, Ribeiro CM, Gambari R, Becq F et al. (2008) Anti-inflammatory effect of miglustat in bronchial epithelial cells. *J Cyst Fibros* 7: 555–565

47 Norez C, Antigny F, Noel S, Vandebrouck C, Becq F (2009) A CF respiratory epithelial cell chron-
ically treated by miglustat acquires a non-CF like phenotype. *Am J Respir Cell Mol Biol* ePub ahead of print: Jan 8

48 Vertex (2009) Trial to enrol approximately 90 patients with the F508del CFTR mutation. *Business Wire*

49 Kelley TJ, al-Nakkash L, Drumm ML (1995) CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. *Am J Respir Cell Mol Biol* 13: 657–664

50 Smith SN, Middleton PG, Chadwick S, Jaffe A, Bush KA, Rolleston S, Farley R, Delaney SJ, Wainwright B, Geddes DM et al. (1999) The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. *Am J Respir Cell Mol Biol* 20: 129–134

51 Mall M, Kunzelmann K (2005) Correction of the CF defect by curcumin: hypes and disappointments. *Bioessays* 27: 9–13

52 Andersson C, Roomans GM (2000) Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. *Eur Respir J* 15: 937–941

53 Smith SN, Middleton PG, Chadwick S, Jaffe A, Bush KA, Rolleston S, Farley R, Delaney SJ, Wainwright B, Geddes DM et al. (1999) The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. *Am J Respir Cell Mol Biol* 20: 129–134

54 Accurso F, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, Sagel SD, Boyle MP, Uler AZ, Upadhyay D et al. (2008) Interim results of phase 2a of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. *Pediatric Pulmonology* Suppl. 30: 289

55 Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW (2007) Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. *Am J Respir Crit Care Med* 176: 362–369

56 Kellerman D, Rossi Mospan A, Engels J, Schaber J, Gorden J, Smiley L (2008) Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. *Palm Pharmacoal Ther* 21: 600–607

57 Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Doring G, Ratjen F (2007) Inhalation of Moli1901 in patients with cystic fibrosis. *Chest* 131: 1461–1466

58 Zeitlin PL, Boyle MP, Guggino WB, Molina L (2004) A phase I trial of intranasal Moli1901 for cystic fibrosis. *Chest* 125: 143–149

59 Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B et al. (2008) Pharmacological properties of N-(3,5-diamino-6-chloroprazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy) phenyl]-butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. *J Pharmacoal Exp Ther* 325: 77–88

60 Plane C, Caughey GH (2007) Regulation of the epithelial Na+ channel by peptidases. *Curr Top Dev Biol* 78: 23–46

61 Coote K, Atherton-Watson HC, Sugar R, Young A, MacKenzie-Beevor A, Gosling M, Bhalay G, Bloomfield G, Dunstan A, Bridges RJ et al. (2009) Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. *J Pharmacoal Exp Ther* 329: 764–774

62 Rowe SM, Reeves G, Young H, Fulton JC, Sthanam M, Abbi S, Roberts A, Renard D, Harris JL, Danahay H et al. (2008) Correction of sodium transport with nasal administration of the prostasin inhibitor QAU145 in CF subjects. *Pediatric Pulmonology* Suppl. 31: 295

63 Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. *Cell* 75: 207–216

64 Griesenbach U, Alton EW (2009) Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. *Adv Drug Deliv Rev* 61: 128–139

65 Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT (1996) A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. *Proc Natl Acad Sci U S A* 93: 5731–5736

66 Palmer DJ, Ng P (2005) Helper-dependent adenoviral vectors for gene therapy. *Hum Gene Ther* 16: 1–16

67 Hiatt PW, Brunetti-Pierri N, McConnell R, Palmer D, Grove N, Finegold M, Beaudet A, Ng P (2008) Pulmonary transduction in nonhuman primates by HDAd: Duration of transgene expression and vector re-administration. *Pediatric Pulmonology* Suppl. 31: 297

68 Firote T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R (1996) A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with...
mild lung disease. *Hum Gene Ther* 7: 1145–1159

69 Wagner JA, Messner AH, Moran ML, Daifuku R, Koyunaka K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S et al. (1999) Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. *Laryngoscope* 109: 266–274

70 Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, Gardner P (1998) Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. *Lancet* 351: 1702–1703

71 Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK et al. (2002) Phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. *Hum Gene Ther* 13: 1349–1359

72 Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC (2001) A Phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. *Hum Gene Ther* 12: 1907–1916

73 Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K et al. (2003) Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. *Hum Gene Ther* 14: 1079–1088

74 Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL et al. (2007) Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. *Hum Gene Ther* 18: 726–732

75 Moss RB, Rodman D, Spencer LT, Aitken ML, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B et al. (2004) Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. *Chest* 125: 509–521

76 Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. *J Virol* 72: 1438–1445

77 Halbert CL, Allen JM, Miller AD (2001) Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. *J Virol* 75: 6615–6624

78 Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA (2000) Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. *J Virol* 74: 3852–3858

79 Halbert CL, Lam SL, Miller AD (2007) High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. *Hum Gene Ther* 18: 344–354

80 Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD (1997) Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. *J Virol* 71: 5932–5941

81 Halbert CL, Standaert TA, Wilson CB, Miller AD (1998) Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. *J Virol* 72: 9795–9805

82 Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD (2000) Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. *J Virol* 74: 1525–1532

83 Sumner-Jones SG, Gill DR, Hyde SC (2007) Lack of repeat transduction by rAAV5/5 vectors in the mouse airway. *J Virol* 81: 12360–12367

84 Limberis MP, Wilson JM (2006) Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. *Proc Natl Acad Sci USA* 103: 12993–12998

85 Ostedgaard LS, Randak C, Rokhina T, Karp P, Vermeer D, Ashbourne Excoffon KJ, Welsh MJ (2003) Effects of C-terminal deletions on cystic fibrosis transmembrane conductance regulator function in cystic fibrosis airway epithelia. *Proc Natl Acad Sci USA* 100: 1937–1942

86 Ostedgaard LS, Rokhina T, Karp PH, Lashmit P, Afiome S, Schmidt M, Zabner J, Stinski MF, Chiorini JA, Welsh MJ (2005) A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. *Proc Natl Acad Sci USA* 102: 2952–2957

87 Ostedgaard LS, Zabner J, Vermeer DW, Rokhina T, Karp PH, Stecenko AA, Randak C, Welsh MJ (2002) CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo. *Proc Natl Acad Sci USA* 99: 3093–3098
88 Zhang L, Wang D, Fischer H, Fan PD, Widdicombe JH, Kan YW, Dong JY (1998) Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc Natl Acad Sci USA 95: 10158–10163
89 Fischer AC, Smith CI, Cebotaru L, Zhang X, Askin FB, Wright J, Guggino SE, Adams RJ, Flotte T, Guggino WB (2007) Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther 15: 756–763
90 Mueller C, Torrez D, Braag S, Martino A, Clarke T, Campbell-Thompson M, Flotte TR (2008) Partial correction of the CFTR-dependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene. J Gene Med 10: 51–60
91 Allocca M, Doria M, Petrillo M, Colella P, Garcia-Hoyos M, Gibbs D, Kim SR, Maguire A, Rex TS, Di Vicino U et al. (2008) Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 118: 1955–1964
92 Liu X, Luo M, Guo C, Yan Z, Wang Y, Lei-Butters DC, Engelhardt JF (2009) Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther 17: 285–293
93 Ferrari S, Griesenbach U, Shiraki-Iida T, Shu T, Hironaka T, Hou X, Williams J, Zhu J, Jeffery PK, Geddes DM et al. (2004) A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther 11: 1659–1664
94 Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, Collins PL, Pickles RJ (2005) Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 79: 1113–1124
95 Ferrari S, Griesenbach U, Iida A, Farley R, Wright AM, Zhu J, Munkonge FM, Smith SN, You J, Ban H et al. (2007) Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther 14: 1371–1379
96 Griesenbach U, Geddes DM, Alton EW (2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13: 1061–1067
97 Rawlins EL, Hogan BL (2008) Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol 295: L231–234
98 Limberis M, Anson DS, Fuller M, Parsons DW (2002) Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 13: 1961–1970
99 Sinn PL, Hickey MA, Staber PD, Dylla DE, Jeffers SA, Davidson BL, Sanders DA, McCray PB Jr, (2003) Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol 77: 5902–5910
100 Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB Jr, (2005) Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 79: 12818–12827
101 Kobinger GP, Limberis MP, Somanathan S, Schumber G, Bell P, Wilson JM (2007) Human immunodeficiency virus vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum Gene Ther 18: 413–422
102 Kobayashi M, Iida A, Ueda Y, Hasegawa M (2003) Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 77: 2607–2614
103 Mitomo K, Griesenbach U, Inoue M, Washizawa K, Fujiawa S, Iwasaki H, Somerton L, Farley R, Singh C, Hasegawa M et al. (2007) Potential airway stem/progenitor cell integration after transduction with a lentiviral vector pseudo-typed with Sendai virus envelope proteins. Pediatric Pulmonology Suppl. 30
104 Nishikawa M, Hashida M (2002) Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 25: 275–283
105 Ratko TA, Cummings JP, Blebea J, Matuszewski KA (2003) Clinical gene therapy for nonmalignant disease. Am J Med 115: 560–569
106 Rosenecker J, Huth S, Rudolph C (2006) Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr Opin Mol Ther 8: 439–445
107 Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG et al. (1999) Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353: 947–954
108 Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH, Meeker DP, Young KR, Schoumacher RA, Weatherly MR et al. (2001) A clinical inflammatory syndrome attributable to
aerosolized lipid-DNA administration in cystic fibrosis. *Hum Gene Ther* **12**: 751–761
109 Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K et al. (2000) A Toll-like receptor recognizes bacterial DNA. *Nature* **408**: 740–745
110 Scheule RK (2000) The role of CpG motifs in immunostimulation and gene therapy. *Adv Drug Deliv Rev* **44**: 119–134
111 Hyde SC, Pringle IA, Abdullah S, Lawton AE, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG et al. (2008) CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. *Nat Biotechnol* **26**: 549–551
112 Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH (2001) High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. *Mol Ther* **4**: 75–82
113 Gill DR, Smyth SE, Goddard CA, Pringle IA, Higgins CF, Colledge WH, Hyde SC (2001) Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. *Gene Ther* **8**: 1539–1546
114 Chow Y-H, Plumb J, Wen Y, Steer B, Lu Z, Hu J (2000) Targeting transgene expression to airway epithelia and submucosal glands, prominent sites of human CFTR expression. *Mol Ther* **2**: 359–367
115 Ostrowski LE, Hutchins JR, Zakel K, O’Neal WK (2003) Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter. *Mol Ther* **8**: 637–645
116 McLachlan G, Baker A, Tennant P, Gordon C, Vrettou C, Renwick L, Blundell R, Cheng SH, Scheule RK, Davies L et al. (2007) Optimizing aerosol gene delivery and expression in the ovine lung. *Mol Ther* **15**: 348–354
117 Davies LA, McLachlan G, Sumner-Jones SG, Ferguson D, Baker A, Tennant P, Gordon C, Vrettou C, Baker E, Zhu J et al. (2008) Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. *Mol Ther* **16**: 1283–1290
118 Aneja MK, Imker R, Rudolph C (2007) Phage phiC31 integrase-mediated genomic integration and long-term gene expression in the lung after nonviral gene delivery. *J Gene Med* **9**: 967–975
119 Liu G, Li D, Pasumarty MK, Kowalczyk TH, Gedeon CR, Hyatt SL, Payne JM, Miller TJ, Brunovskis P, Fink TL et al. (2003) Nanoparticles of compacted DNA transfected postmitotic cells. *J Biol Chem* **278**: 32578–32586
120 Chen X, Kube DM, Cooper MJ, Davis PB (2008) Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. *Mol Ther* **16**: 333–342
121 Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR et al. (2004) Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. *Hum Gene Ther* **15**: 1255–1269
122 Collaco JM, Cutting GR (2008) Update on gene modifiers in cystic fibrosis. *Curr Opin Pulm Med* **14**: 559–566
123 Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, Harley JB, Kilpatrick JR, Langefeld CD, Williams AH et al. (2009) Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. *Nature* **458**: 1039–1042
124 Hollox EJ, Davies J, Griesenbach U, Burgess J, Alton EW, Armour JA (2005) Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. *J Negat Results Biomed* **4**: 9
125 Tesse R, Cardinale F, Santostasi T, Polizzi A, Manca A, Mappa L, Iacoviello G, De Robertis F, Logrillo VP, Armenio L (2008) Association of beta-defensin-1 gene polymorphisms with Pseudomonas aeruginosa airway colonization in cystic fibrosis. *Genes Immun* **9**: 57–60
126 Laki J, Laki I, Nemeth K, Ujhelyi R, Bede O, Endreffy E, Bolbas K, Gyurkovits K, Csizser E, Solyom E et al. (2006) The 8.1 ancestral MHC haplotype is associated with delayed onset of colonization in cystic fibrosis. *Int Immunol* **18**: 1585–1590
127 Corvol H, Boelle PY, Brousseau J, Krumpfer C, Hanrion-Caude A, Flamant C, Muselet-Charlier C, Boule M, Faurex B et al. (2008) Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. *Pediatr Pulmonol* **43**: 1224–1232
128 Tesse R, Cardinale F, Santostasi T, Polizzi A, Mappa L, Manca A, De Robertis F, Silecchia O, Armenio L (2008) Association of interleukin-10 gene haplotypes with Pseudomonas aeruginosa airway colonization in cystic fibrosis. *J Cyst Fibros* **7**: 329–332
129 Nichols DP, Konstan MW, Chmiel JF (2008) Anti-inflammatory therapies for cystic fibrosis-related lung disease. *Clin Rev Allergy Immunol* **35**: 135–153
130 Vij N, Mazur S, Zeitlin PL (2009) CFTR is a negative regulator of NFkB mediated innate
immune response. *PLoS ONE* 4: e4464

Lambert G, Becker B, Schreiber R, Boucherot A, Reth M, Kunzelmann K (2001) Control of cystic fibrosis transmembrane conductance regulator expression by BAP31. *J Biol Chem* 276: 20340–20345